Page last updated: 2024-11-02

pargyline and Coronary Disease

pargyline has been researched along with Coronary Disease in 3 studies

Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.

Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lamontagne, D1
Yamaguchi, N1
Ribuot, C1
de Champlain, J1
Nadeau, R1
Carlsson, L1
Graefe, KH1
Trendelenburg, U1
Vidt, DG1

Other Studies

3 other studies available for pargyline and Coronary Disease

ArticleYear
Reduction of tissue noradrenaline content in the isolated perfused rat heart during ischemia: importance of monoamine oxidation.
    Canadian journal of physiology and pharmacology, 1991, Volume: 69, Issue:8

    Topics: Animals; Coronary Disease; In Vitro Techniques; Male; Monoamine Oxidase; Myocardium; Norepinephrine;

1991
Early intraneuronal mobilization and deamination of noradrenaline during global ischemia in the isolated perfused rat heart.
    Naunyn-Schmiedeberg's archives of pharmacology, 1987, Volume: 336, Issue:5

    Topics: Animals; Calcium; Coronary Circulation; Coronary Disease; Deamination; Desipramine; Heart; In Vitro

1987
An approach to the medical treatment of hypertension in the aged.
    Geriatrics, 1969, Volume: 24, Issue:4

    Topics: Age Factors; Aged; Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Diuretics;

1969